Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study
Keywords: Metastatic melanoma; BRAF inhibitors; BRAFi; MEKi;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
Keywords: Binimetinib (PubChem CID: 10288191); Cobimetinib (PubChem CID: 16222096); Dabrafenib (PubChem CID: 44462760); Encorafenib (PubChem CID: 50922675); Trametinib (PubChem CID: 11707110); Vemurafenib (PubChem CID: 42611257); ATC; adoptively transferred T cells
Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma
Keywords: AUC; area under the curve; BMI; body mass index; BRAFi; BRAF-inhibitor; Cmin; trough plasma concentration; CV; coefficient of variation; CYP; cytochrome P450; MEKi; MEK-inhibitor; PK/PD; pharmacokinetics and pharmacodynamics; ROC; receiver operating chara
Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma
Keywords: AMPK; AMP-activated kinase; BRAFi; BRAF inhibitor; ERK; extracellular signal-regulated kinase; ERKi; ERK inhibitor; PGC1α; peroxisome proliferator-activated receptor gamma, coactivator 1-α; MEK; MAPK/ERK kinase; MEKi; MEK inhibitor; mTOR; mechanistic ta
The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice
Keywords: BRAFi; BRAF inhibitor; HPV; human papillomavirus; SCC; squamous cell carcinoma;
An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients
Keywords: BRAFi; BRAF inhibitors; MEKi; MEK inhibitors; Cmin; Trough concentration; CV; Coefficient of variation; EMA; European Medical Agency; ESI; Electrospray ionization; LC-UV; Liquid chromatography combined to UV detection; LLOQ; Low limit of quantification; M
Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma
Keywords: BRAFi; BRAF selective inhibitors; cSCC; cutaneous squamous cell carcinoma; ERK; extracellular signal-regulated kinase; MAPK; mitogen-activated protein kinase;
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort
Keywords: anti-programmed cell death-1; eczema; immune reaction; immunotherapy; lichenoid reaction; metastatic melanoma; vitiligo; AE; adverse event; BRAFI; BRAF inhibitor; FDA; Food and Drug Administration; PD; programmed cell death; SCC; squamous cell carcinoma;
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
Keywords: cutaneous adverse event; histology; inflammation; rash; squamous cell carcinoma; therapy; AK; actinic keratosis; bid; twice a day; BRAFi; BRAF inhibitor; CI; confidence interval; FDA; Food and Drug Administration; KA; keratoacanthoma; MAPK; mitogen-activa
Melanoma Brain Metastases and Vemurafenib: Need for Further Investigation
Keywords: BBB; blood-brain barrier; BRAFi; BRAF inhibitor; CNS; central nervous system; FDA; Food and Drug Administration; MRI; magnetic resonance imaging; WBRT; whole-brain radiation therapy;